Drug intelligence / Profile preview

P947

Development stage: Unknown
Lead developer: Guerbet
Modality: Small Molecules
Administration: Intravenous

Overview

P947 is a small molecule gadolinium-based contrast agent developed for magnetic resonance imaging (MRI) to target and visualize matrix metalloproteinase (MMP) activity in tissues. It is designed to bind specifically to MMPs, which are upregulated in various pathological conditions, including atherosclerosis and cancers, enabling enhanced imaging of disease-associated tissue remodeling. The agent is not approved for general clinical use and remains investigational.

Targets

MMP12 (Macrophage Metalloelastase)

Beyond the preview

Go deeper on P947.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P947.

Explore the full profile